By Adriano Marchese
Enanta Pharmaceuticals said it saw positive results from its recent study evaluating a treatment for respiratory syncytial virus in newborns, also known as RSV.
The clinical-stage biotechnology company said Monday that topline results from the phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with RSV were positive.
RSV usually presents itself mildly, with people developing cold-like symptoms, but it is the leading cause of infant hospitalization in the U.S., according to the Centers for Disease Control and Prevention.
"Zelicapavir demonstrated an antiviral effect on both primary endpoints, as well as secondary virology endpoints," Chief Medical Officer Scott Rottinghaus said.
Enanta said it also saw a favorable safety profile for the drug over the initial five-day dosing period and through 23 days of follow-up.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 09, 2024 07:12 ET (12:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。